Dimethyltryptamine is under clinical development by Viridia Life Sciences and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dimethyltryptamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dimethyltryptamine overview

Dimethyltryptamine (DMT) is under development for the treatment of depression. DMT is an active ingredient in Ayahuasca and acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A). It is administered as buccal transmucosal film and also through intravenous route.

Viridia Life Sciences overview

Viridia Life Sciences (Viridia Life) is a biotechnology company that engaged in developing a digital therapeutic including cognitive behavioral therapy, group therapy, and patient monitoring post dosing. The company is headquartered in New Castle, the US.

For a complete picture of Dimethyltryptamine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.